Deerland Enzymes & Probiotics’ (Kennesaw, GA) genome-sequenced probiotic Bacillus subtilis strain DE111 has been given a Natural Product Number (NPN) by Health Canada. Per Canada’s 2004-effective Natural Health Products Regulations, all natural health products must receive both a product license and an NPN in order to be sold in Canada. The NPN is 80077102.
DE111 is a clinically tested strain that supports digestive and immune health. In those human studies, DE111 demonstrated its efficacy in controlling microbial populations, aiding digestion, and encouraging overall health, the company says. In addition, the research showed that DE111 contained no plasmids (pieces of DNA that replicate independently of the chromosomes) or antibiotic-resistant or deleterious genes. DE111 protects the microbes by forming spores, an ability that enables to bacteria to remain viable under various temperature and pH conditions and makes it highly usable in supplements as well as in food and beverages, according to the company.
“We appreciate the rigor of the process for product approval in Canada, and we’re pleased that DE111 has met the justifiably stringent standards that are in place for all natural health products,” said Scott Ravech, CEO, Deerland Enzymes, in a press release. “Based on the success of DE111 in the United States, we are excited to be able to offer this science-backed probiotic product to Canadian consumers, and we expect to see a significant growth in demand.”